H.R. 5160, Stem Cell Therapeutic and Research Reauthorization Act of 2025
Pass the Stem Cell Therapeutic and Research Reauthorization Act of 2025.
Occurrences
Evidence
The House Energy and Commerce Health Subcommittee reported H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act of 2025, to the full committee by voice vote.
The House Energy and Commerce Committee reported H.R. 5160 to the full House as amended by a roll call vote of 46 yeas to 0 nays.
Assessments
The bill advanced through House committee stages in May 2026, including subcommittee and full committee action, but there is no evidence that it passed the House and Senate or was enacted. That means Calvert showed legislative effort, but the promised outcome of passing the Stem Cell Therapeutic and Research Reauthorization Act of 2025 was not delivered.